Complete financial analysis of BELLUS Health Inc. (BLU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BELLUS Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Eagle Gold Corp. (AE.V) Income Statement Analysis – Financial Results
- Stamper Oil & Gas Corp. (STMGF) Income Statement Analysis – Financial Results
- Puequ CO.,LTD. (9264.T) Income Statement Analysis – Financial Results
- Ace Technologies Corp. (088800.KQ) Income Statement Analysis – Financial Results
- Assicurazioni Generali S.p.A. (G.MI) Income Statement Analysis – Financial Results
BELLUS Health Inc. (BLU)
About BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00K | 16.00K | 15.00K | 26.79K | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.12M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.74M | 2.91M | 109.80K | 0.00 | 2.25M | 5.52M | 118.83K |
| Cost of Revenue | 3.51B | 2.22B | 1.43B | 994.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 693.62K | -470.29K | 0.00 | 0.00 | -1.16M | 0.00 | 0.00 |
| Gross Profit | -3.51B | -2.22B | -1.43B | -994.49M | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.26M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.05M | 3.38M | 109.80K | 0.00 | 3.41M | 5.52M | 118.83K |
| Gross Profit Ratio | -21,967,104.08% | -13,887,173.94% | -9,536,119.55% | -3,711,740.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 106.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.71% | 116.14% | 100.00% | 0.00% | 151.65% | 100.00% | 100.00% |
| Research & Development | 58.89M | 59.79M | 23.73M | 20.00M | 5.28M | 2.87M | 1.13M | 931.76K | 1.46M | 1.19M | 998.16K | 1.29M | 7.05M | 10.04M | 23.60M | 55.45M | 49.54M | 40.61M | 24.42M | 5.71M | 8.03M | 6.56M | 3.19M |
| General & Administrative | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 0.00 | 7.69M | 8.57M | 11.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 611.90K | 3.71M | 6.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 3.47M | 8.30M | 12.28M | 18.45M | 15.17M | 14.67M | 23.25M | 18.29M | 5.75M | 2.44M | 396.43K | 1.02M |
| Other Expenses | -491.00K | -754.00K | -507.00K | -543.53K | -479.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 653.38K | 5.34M | -5.05M | 13.11M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 65.73M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Cost & Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 66.42M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Interest Income | 5.08M | 233.00K | 1.05M | 1.16M | 265.78K | 63.62K | 74.40K | 104.49K | 170.56K | 189.71K | 137.71K | 105.78K | 151.98K | 102.00K | 907.00K | 0.00 | 2.36M | 2.08M | 0.00 | 520.42K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 78.00K | 55.00K | 39.00K | 22.97K | 3.67K | 8.75K | 8.18K | 7.93K | 89.59K | 133.36K | 220.14K | 333.01K | 526.92K | 324.00K | 271.00K | 0.00 | 151.45K | 461.68K | 0.00 | 46.37K | 232.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 426.00K | 1.22M | 1.28M | 325.25K | 63.62K | 49.10K | 104.49K | 345.43K | 658.36K | -17.49M | 45.05K | 1.47M | 693.00K | 1.88M | 399.00K | 335.82K | 2.60M | 1.70M | 497.67K | 585.56K | 278.82K | 224.15K |
| EBITDA | -72.76M | -72.86M | -31.72M | -24.82M | -6.95M | -4.46M | -1.51M | 28.10K | -1.78M | -2.43M | -21.12M | -1.71M | -13.22M | -7.21M | -46.07M | -66.97M | -62.16M | -60.94M | -42.60M | -11.46M | -8.22M | -1.44M | -4.09M |
| EBITDA Ratio | -454,768.75% | -455,362.50% | -211,453.33% | -92,637.22% | -27,038.13% | -3,396.99% | -107.29% | 0.97% | -87.04% | -114.72% | -914.36% | -56.95% | -549.21% | 6,215.52% | -7,888.36% | -4,443.66% | -2,266.69% | -2,091.58% | -38,800.14% | 0.00% | -365.10% | -26.07% | -3,440.36% |
| Operating Income | -77.88M | -73.28M | -32.94M | -26.10M | -7.27M | -4.52M | -1.56M | -76.39K | -2.13M | -3.09M | -3.64M | -1.76M | -14.69M | -21.12M | -45.66M | -68.66M | -63.68M | -63.69M | -44.30M | -11.95M | -8.81M | -1.72M | -4.31M |
| Operating Income Ratio | -486,768.75% | -458,025.00% | -219,613.33% | -97,431.66% | -28,303.89% | -3,445.47% | -110.78% | -2.63% | -103.91% | -145.79% | -157.40% | -58.45% | -610.09% | 18,204.31% | -7,817.64% | -4,555.81% | -2,321.87% | -2,185.81% | -40,350.15% | 0.00% | -391.10% | -31.13% | -3,629.00% |
| Total Other Income/Expenses | 1.86M | 1.86M | 1.19M | -280.19K | 603.51K | 3.08M | -86.30K | 348.78K | 389.37K | 2.18M | -9.60M | 5.34M | -5.05M | 12.89M | -2.57M | -12.42M | -999.45K | 1.38M | 714.67K | -1.35M | 74.51K | 0.00 | 316.65K |
| Income Before Tax | -76.02M | -71.42M | -31.76M | -26.39M | -6.67M | -1.44M | -1.65M | 272.40K | -1.74M | -911.93K | -13.24M | 3.58M | -19.73M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -13.30M | -8.73M | 0.00 | -4.00M |
| Income Before Tax Ratio | -475,125.00% | -446,393.75% | -211,713.33% | -98,477.40% | -25,955.23% | -1,098.79% | -116.90% | 9.39% | -84.89% | -43.04% | -573.11% | 119.24% | -819.68% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -387.79% | 0.00% | -3,362.52% |
| Income Tax Expense | 60.00K | -199.00K | 39.00K | 22.97K | -607.18K | 48.51K | 11.16K | -19.46K | -42.21K | -617.97K | 18.44M | 227.23K | 374.94K | 13.44M | 1.32M | -1.94M | -1.50M | -2.04M | -626.83K | -365.56K | 152.98K | 58.14K | -227.53K |
| Net Income | -76.08M | -71.22M | -31.80M | -26.41M | -6.06M | -1.49M | -1.61M | 145.57K | -1.66M | -818.96K | -13.32M | 3.35M | -20.11M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -12.93M | -8.89M | -1.78M | -3.77M |
| Net Income Ratio | -475,500.00% | -445,150.00% | -211,973.33% | -98,563.12% | -23,592.29% | -1,135.76% | -114.05% | 5.02% | -81.27% | -38.65% | -576.81% | 111.68% | -835.26% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -394.58% | -32.18% | -3,171.04% |
| EPS | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | 1.38 | -10.28 | -6.34 | -105.15 | -198.86 | -181.01 | -196.26 | -156.38 | -52.10 | -53.29 | -11.00 | -32.16 |
| EPS Diluted | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | -0.67 | -10.28 | -6.30 | -105.15 | -198.86 | -181.01 | -187.15 | -137.04 | -44.64 | -49.86 | -11.00 | -32.16 |
| Weighted Avg Shares Out | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 2.47M | 1.96M | 1.30M | 458.62K | 407.69K | 357.31K | 317.48K | 278.73K | 248.27K | 166.73K | 161.45K | 117.17K |
| Weighted Avg Shares Out (Dil) | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 6.04M | 1.96M | 1.31M | 458.62K | 407.69K | 357.31K | 332.93K | 318.06K | 289.73K | 178.21K | 161.45K | 117.17K |
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its amended and restated short form base shelf prospectus dated December 14, 2021, amending...
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today announced a positive End-of-Phase 2 (“EOP2”)...
Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
BELLUS Health to Participate in the William Blair Biotech Focus Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President...
This Small-Cap Innovator is Flying High
We may be turning the page to a new chapter where small-cap stocks re-establish their supremacy.
Here's Why Bellus Health (BLU) is a Great Momentum Stock to Buy
Does Bellus Health (BLU) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Are Medical Stocks Lagging Bellus Health (BLU) This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
BELLUS Health to Participate in the Jefferies Healthcare Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President...
Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports